iA Global Asset Management Inc. Has $1.64 Million Stake in Insulet Corporation $PODD

iA Global Asset Management Inc. grew its stake in Insulet Corporation (NASDAQ:PODD) by 18.8% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,209 shares of the medical instruments supplier’s stock after purchasing an additional 823 shares during the period. iA Global Asset Management Inc.’s holdings in Insulet were worth $1,637,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of the stock. Sequoia Financial Advisors LLC grew its position in Insulet by 2.3% in the 2nd quarter. Sequoia Financial Advisors LLC now owns 2,017 shares of the medical instruments supplier’s stock worth $634,000 after purchasing an additional 45 shares during the last quarter. Nissay Asset Management Corp Japan ADV boosted its position in shares of Insulet by 0.6% during the 1st quarter. Nissay Asset Management Corp Japan ADV now owns 8,462 shares of the medical instruments supplier’s stock valued at $2,222,000 after acquiring an additional 48 shares in the last quarter. Mather Group LLC. boosted its position in shares of Insulet by 4.4% during the 2nd quarter. Mather Group LLC. now owns 1,147 shares of the medical instruments supplier’s stock valued at $360,000 after acquiring an additional 48 shares in the last quarter. Brooklyn Investment Group boosted its position in shares of Insulet by 7.0% during the 1st quarter. Brooklyn Investment Group now owns 795 shares of the medical instruments supplier’s stock valued at $209,000 after acquiring an additional 52 shares in the last quarter. Finally, Cooper Financial Group boosted its position in shares of Insulet by 5.7% during the 1st quarter. Cooper Financial Group now owns 1,079 shares of the medical instruments supplier’s stock valued at $283,000 after acquiring an additional 58 shares in the last quarter.

Insider Transactions at Insulet

In other Insulet news, SVP Laetitia Cousin sold 797 shares of the business’s stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $348.81, for a total value of $278,001.57. Following the completion of the transaction, the senior vice president directly owned 3,890 shares of the company’s stock, valued at approximately $1,356,870.90. The trade was a 17.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, SVP Prem Singh sold 687 shares of the business’s stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $347.49, for a total transaction of $238,725.63. Following the completion of the transaction, the senior vice president directly owned 3,456 shares of the company’s stock, valued at approximately $1,200,925.44. This represents a 16.58% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 0.39% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on PODD shares. Canaccord Genuity Group lifted their target price on shares of Insulet from $353.00 to $399.00 and gave the company a “buy” rating in a research report on Monday, September 29th. Barclays lifted their target price on shares of Insulet from $266.00 to $300.00 and gave the company an “equal weight” rating in a research report on Thursday, August 21st. JPMorgan Chase & Co. lifted their target price on shares of Insulet from $340.00 to $415.00 and gave the company an “overweight” rating in a research report on Friday, September 12th. Royal Bank Of Canada lifted their target price on shares of Insulet from $350.00 to $365.00 and gave the company an “outperform” rating in a research report on Friday, October 10th. Finally, Piper Sandler lifted their target price on shares of Insulet from $320.00 to $360.00 and gave the company an “overweight” rating in a research report on Tuesday, September 16th. One investment analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $352.11.

Insulet Price Performance

NASDAQ:PODD opened at $318.77 on Tuesday. The firm has a market cap of $22.44 billion, a PE ratio of 96.89, a price-to-earnings-growth ratio of 2.64 and a beta of 1.40. Insulet Corporation has a 12 month low of $230.05 and a 12 month high of $353.50. The company has a quick ratio of 1.81, a current ratio of 2.26 and a debt-to-equity ratio of 0.64. The company’s 50-day moving average price is $326.38 and its two-hundred day moving average price is $308.18.

Insulet (NASDAQ:PODD) last released its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $1.17 EPS for the quarter, beating analysts’ consensus estimates of $0.92 by $0.25. The firm had revenue of $649.10 million for the quarter, compared to analyst estimates of $612.31 million. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The company’s revenue for the quarter was up 32.9% compared to the same quarter last year. During the same period in the previous year, the business earned $0.55 earnings per share. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. On average, equities analysts anticipate that Insulet Corporation will post 3.92 EPS for the current fiscal year.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.